ES2186576B1 - Acido 2-hidroxioleico para utilizar como medicamento. - Google Patents

Acido 2-hidroxioleico para utilizar como medicamento.

Info

Publication number
ES2186576B1
ES2186576B1 ES200102269A ES200102269A ES2186576B1 ES 2186576 B1 ES2186576 B1 ES 2186576B1 ES 200102269 A ES200102269 A ES 200102269A ES 200102269 A ES200102269 A ES 200102269A ES 2186576 B1 ES2186576 B1 ES 2186576B1
Authority
ES
Spain
Prior art keywords
hydroxyoleic
acid
agent
medicinal product
hydroxyoleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200102269A
Other languages
English (en)
Spanish (es)
Other versions
ES2186576A1 (es
Inventor
Pablo Vicente Escriba Ruiz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitat de les Illes Balears
Original Assignee
Universitat de les Illes Balears
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200102269A priority Critical patent/ES2186576B1/es
Application filed by Universitat de les Illes Balears filed Critical Universitat de les Illes Balears
Priority to CN2008100917937A priority patent/CN101259121B/zh
Priority to CA2463348A priority patent/CA2463348C/en
Priority to ES02783094T priority patent/ES2261752T3/es
Priority to CNB028201132A priority patent/CN100471492C/zh
Priority to DE60210488T priority patent/DE60210488T2/de
Priority to MXPA04003255A priority patent/MXPA04003255A/es
Priority to EP02783094A priority patent/EP1435235B1/en
Priority to AT02783094T priority patent/ATE322261T1/de
Priority to PCT/ES2002/000475 priority patent/WO2003030891A1/es
Priority to RU2004114229/15A priority patent/RU2310445C2/ru
Priority to JP2003533923A priority patent/JP4737931B2/ja
Priority to PT02783094T priority patent/PT1435235E/pt
Priority to BRPI0213165A priority patent/BRPI0213165B8/pt
Priority to US10/488,726 priority patent/US20050014831A1/en
Priority to CN2008100917941A priority patent/CN101259122B/zh
Publication of ES2186576A1 publication Critical patent/ES2186576A1/es
Application granted granted Critical
Publication of ES2186576B1 publication Critical patent/ES2186576B1/es
Priority to US12/082,938 priority patent/US7851507B2/en
Priority to US12/939,641 priority patent/US8778995B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES200102269A 2001-10-11 2001-10-11 Acido 2-hidroxioleico para utilizar como medicamento. Expired - Fee Related ES2186576B1 (es)

Priority Applications (18)

Application Number Priority Date Filing Date Title
ES200102269A ES2186576B1 (es) 2001-10-11 2001-10-11 Acido 2-hidroxioleico para utilizar como medicamento.
JP2003533923A JP4737931B2 (ja) 2001-10-11 2002-10-09 医薬品の製造におけるヒドロキシオレイン酸及び類似化合物の使用
ES02783094T ES2261752T3 (es) 2001-10-11 2002-10-09 Uso del acido hidroxioleico y compuestos similares en la produccion de medicamentos.
CNB028201132A CN100471492C (zh) 2001-10-11 2002-10-09 羟油酸及相关化合物在制备药物中的应用
DE60210488T DE60210488T2 (de) 2001-10-11 2002-10-09 Verwendung von hydroxyölsäure und ähnlicher verbindungen bei der herstellung von medikamenten
MXPA04003255A MXPA04003255A (es) 2001-10-11 2002-10-09 Utilizacion de acido hidrocioleico y compuestos analogos del mismo en la fabricacion de medicamentos.
EP02783094A EP1435235B1 (en) 2001-10-11 2002-10-09 Use of hydroxyoleic acid and similar compounds in the production of medicaments
AT02783094T ATE322261T1 (de) 2001-10-11 2002-10-09 Verwendung von hydroxyölsäure und ähnlicher verbindungen bei der herstellung von medikamenten
PCT/ES2002/000475 WO2003030891A1 (es) 2001-10-11 2002-10-09 Utilizacion del acido hidroxioleico y compuestos analogos del mismo en la fabricacion de medicamentos
BRPI0213165A BRPI0213165B8 (pt) 2001-10-11 2002-10-09 uso de ácido hidroxioléico e compostos relacionados na manufatura de drogas
CN2008100917937A CN101259121B (zh) 2001-10-11 2002-10-09 羟油酸及相关化合物在制备药物中的应用
CA2463348A CA2463348C (en) 2001-10-11 2002-10-09 Use of hydroxyoleic acid and related compounds in the manufacture of drugs
RU2004114229/15A RU2310445C2 (ru) 2001-10-11 2002-10-09 Применение гидроксиолеиновой кислоты и родственных соединений при производстве лекарственных средств
US10/488,726 US20050014831A1 (en) 2001-10-11 2002-10-09 Use of hydroxyoleic acid and similar compounds in the production of medicaments
CN2008100917941A CN101259122B (zh) 2001-10-11 2002-10-09 羟油酸及相关化合物在制备药物中的应用
PT02783094T PT1435235E (pt) 2001-10-11 2002-10-09 Utilizacao de acido hidroxioleico e compostos semelhantes na producao de medicamentos
US12/082,938 US7851507B2 (en) 2001-10-11 2008-04-15 Use of hydroxyoleic acid and related compounds in the manufacture of drugs
US12/939,641 US8778995B2 (en) 2001-10-11 2010-11-04 Use of hydroxyoleic acid and related compounds in the manufacture of drugs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200102269A ES2186576B1 (es) 2001-10-11 2001-10-11 Acido 2-hidroxioleico para utilizar como medicamento.

Publications (2)

Publication Number Publication Date
ES2186576A1 ES2186576A1 (es) 2003-05-01
ES2186576B1 true ES2186576B1 (es) 2004-09-16

Family

ID=8499164

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200102269A Expired - Fee Related ES2186576B1 (es) 2001-10-11 2001-10-11 Acido 2-hidroxioleico para utilizar como medicamento.
ES02783094T Expired - Lifetime ES2261752T3 (es) 2001-10-11 2002-10-09 Uso del acido hidroxioleico y compuestos similares en la produccion de medicamentos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES02783094T Expired - Lifetime ES2261752T3 (es) 2001-10-11 2002-10-09 Uso del acido hidroxioleico y compuestos similares en la produccion de medicamentos.

Country Status (13)

Country Link
US (3) US20050014831A1 (enExample)
EP (1) EP1435235B1 (enExample)
JP (1) JP4737931B2 (enExample)
CN (3) CN101259122B (enExample)
AT (1) ATE322261T1 (enExample)
BR (1) BRPI0213165B8 (enExample)
CA (1) CA2463348C (enExample)
DE (1) DE60210488T2 (enExample)
ES (2) ES2186576B1 (enExample)
MX (1) MXPA04003255A (enExample)
PT (1) PT1435235E (enExample)
RU (1) RU2310445C2 (enExample)
WO (1) WO2003030891A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2229935B1 (es) * 2003-10-10 2006-10-01 Universitat De Les Illes Balears Utilizacion del acido hidroxioleico y compuestos analagos del mismo como aditivos alimentarios funcionales.
JP2009051732A (ja) * 2005-12-13 2009-03-12 Meiji Seika Kaisha Ltd Ｐｐａｒリガンド活性を有する組成物
CN101570481B (zh) * 2008-04-30 2012-02-01 上海医药工业研究院 一种多羟基长链脂肪酸及其分离提取方法和在抑制芳香化酶活性中的应用
ES2342997B1 (es) * 2008-12-09 2011-06-06 Universitat De Les Illes Balears Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.
ES2345241B1 (es) * 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
WO2011089265A1 (en) 2010-01-25 2011-07-28 Bridge Bioresearch Plc Use of fatty acid compounds for lowering blood glucose levels
CN101985420B (zh) * 2010-01-29 2014-04-30 苏州润新生物科技有限公司 油酸酯及其制备方法和在制备用于治疗高血压及其并发症的药物中的应用
ES2401629B1 (es) * 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
WO2013108428A1 (ja) * 2012-01-19 2013-07-25 日本水産株式会社 食欲抑制剤
WO2013132092A1 (en) 2012-03-09 2013-09-12 Pensieve International Plc Use of monounsaturated fatty acid compounds for controlling the body weight of a dog or a cat
ES2734554T3 (es) * 2012-09-26 2019-12-10 Tangent Reprofiling Ltd Combinación de benzo(iso)oxazolpiperidinas con ácido linoleico conjugado
GB201217296D0 (en) 2012-09-27 2012-11-14 Alta Innovations Ltd Method of treatment and/or prevention
WO2016062746A1 (en) 2014-10-21 2016-04-28 Universitat De Les Illes Balears Method for the synthesis of hydroxy-triglycerides and uses thereof for the prevention and treatment of diseases
US10756968B2 (en) 2015-01-26 2020-08-25 Rapid7, Inc. Network resource management devices methods and systems

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001100A1 (en) * 1992-07-01 1994-01-20 Arch Development Corporation METHODS AND COMPOSITIONS FOR INHIBITING 5α-REDUCTASE ACTIVITY
US6214875B1 (en) * 1998-04-14 2001-04-10 Zhenhua Yang Anticancer effects of specific branched-chain fatty acids and related production process

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61297A (ja) * 1984-06-12 1986-01-06 日本油脂株式会社 オレイン酸の製造法
GB8603621D0 (en) * 1986-02-14 1986-03-19 Habib N Modifying lipid structure of cell membranes
JPS6344843A (ja) * 1986-08-13 1988-02-25 Kao Corp 油中水中油型乳化油脂組成物
CN1035925C (zh) * 1988-11-16 1997-09-24 许正 亲细胞非均质分子脂质的制备方法
CN1118228A (zh) * 1995-03-16 1996-03-13 姜训书 松籽果酱
CN1118218A (zh) * 1995-03-16 1996-03-13 姜训书 松籽油的制作方法及松籽保健食用油
GB9506837D0 (en) * 1995-04-03 1995-05-24 Scotia Holdings Plc Triglycerides
PT771817E (pt) * 1995-10-30 2003-06-30 Oleoyl Estrone Developments S Mono-esteres de oleato de estrogenos para o tratamento da obesidade e/ou excesso de peso
US5856537A (en) * 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
DE19727636C1 (de) * 1997-06-28 1998-11-19 Rwe Dea Ag Verfahren zur Herstellung von 2-Alkylcarbonsäuren
CN1212867A (zh) * 1997-09-29 1999-04-07 宋凤亭 防治心脑血管疾病的组合物
DK0948963T3 (da) * 1998-01-21 2003-08-11 Fideline Pacificerende pheromoner til grise med henblik på nedsættelse af stress, angst og aggressivitet
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
WO2002051406A1 (en) * 2000-12-23 2002-07-04 Creighton University Methods for inducing apoptosis and inhibiting proliferation in cancer cells
DE10130491A1 (de) * 2001-06-25 2003-04-17 Heirler Horst Verwendung von mittelkettigen Triglyceriden zur Prävention und Therapie von Adipositas

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001100A1 (en) * 1992-07-01 1994-01-20 Arch Development Corporation METHODS AND COMPOSITIONS FOR INHIBITING 5α-REDUCTASE ACTIVITY
US6214875B1 (en) * 1998-04-14 2001-04-10 Zhenhua Yang Anticancer effects of specific branched-chain fatty acids and related production process

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AWAD ATIF, B. et al.: "18:1 n7 fatty acids inhibit growth and decrease inositol phosphorate release in HT-29 cells compared to n9 fatty acids", Cancer Letters, 1995, Vol. 91 (1), páginas 55-61, ISSN:0304-3835, todo el documento, en particular, resumen. *
DE CATERINA, R. et al.: "The direct effect of injectable cyclosporine and its vehicle, cremophor, on endothelial vascular cell adhesion molecule-1 expression: Ricinoleic acid inhibits coronary artery endothelial activation", Transplantation (Baltimore), (1995), Vol. 60 (3), páginas 270-275, ISSN:0041-1337, todo el documento. *
SEBASTIANO, B. et al.: "Vaccenic acid feeding increases tissue levels of conjugated linoleic acid and supresses development of premalignant lesions in rat mammary gland", Nutrition and Cancer, 2001, Vol. 41 (1-2), páginas 91-97, ISSN:0163-5581, todo el documento, en particular, página 57, columna 2, líneas 7-9. *

Also Published As

Publication number Publication date
BR0213165A (pt) 2004-09-14
US20110136906A1 (en) 2011-06-09
CA2463348C (en) 2011-04-05
US20050014831A1 (en) 2005-01-20
RU2310445C2 (ru) 2007-11-20
WO2003030891A1 (es) 2003-04-17
EP1435235B1 (en) 2006-04-05
US20090082446A1 (en) 2009-03-26
CN101259121B (zh) 2011-04-06
US8778995B2 (en) 2014-07-15
CN101259121A (zh) 2008-09-10
JP4737931B2 (ja) 2011-08-03
ES2186576A1 (es) 2003-05-01
BRPI0213165B1 (pt) 2018-01-23
CN100471492C (zh) 2009-03-25
MXPA04003255A (es) 2005-01-25
CN101259122A (zh) 2008-09-10
CA2463348A1 (en) 2003-04-17
DE60210488D1 (de) 2006-05-18
CN101259122B (zh) 2011-04-06
DE60210488T2 (de) 2006-12-14
PT1435235E (pt) 2006-08-31
US7851507B2 (en) 2010-12-14
JP2005527479A (ja) 2005-09-15
EP1435235A1 (en) 2004-07-07
BRPI0213165B8 (pt) 2021-05-25
ES2261752T3 (es) 2006-11-16
RU2004114229A (ru) 2005-04-20
CN1688302A (zh) 2005-10-26
ATE322261T1 (de) 2006-04-15

Similar Documents

Publication Publication Date Title
ES2186576B1 (es) Acido 2-hidroxioleico para utilizar como medicamento.
BR9915553A (pt) Amidas de ácido antranìlico e seu emprego como medicamento
BR0110486A (pt) Antranilamidas e sua aplicação como medicamento
BRPI0410684A (pt) uso de um peptìdio conjugado a uma proteìna que age como um imunógeno para a produção de anticorpos capazes de reconhecer especificamente qualquer uma das variantes predominantes do peptìdeo beta amilóide aß40 e aß42 na preparação de um medicamento para a prevenção e/ou o tratamento de uma doença e uso de um anticorpo ou um fragmento ativo ou o derivado de um anticorpo que reconhece especificamente qualquer uma das variantes predominantes do peptìdio beta amilóide, aß40 e aß42, na preparação de um medicamento para prevenção e/ou tratamento de uma doença
CY1105082T1 (el) Χρηση της φλιβανσepινης στην αγωγη διαταραχων της σεξουαλικης επιθυμιας
HUP0402217A2 (hu) Platinaszármazékot tartalmazó gyógyászati készítmények
KR960700742A (ko) 아토피성질환 치료약(atopic disease remedy)
BR0208636A (pt) Agente terapêutico para doenças de artrìtides crÈnicas de doenças relacionadas com inf‰ncia
BR9916224A (pt) Forma de dosagem farmacêutica oral, processos para a manufatura de uma forma de dosagem fixa, para o tratamento e a profilaxia de distúrbios gastrintestinais e para evitar efeitos colaterias gastrintestinais, uso de uma forma de dosagem, combinação, e, embalagem tipo ampola
SE0303571D0 (sv) Medical product for moisture-sensitive medicaments
NO20085100L (no) Nye forbindelser
ATE543804T1 (de) Neue verbindungen
YU84503A (sh) Upotreba azitromicina za pripremanje leka za lečenje neinfektivnih inflamatornih oboljenja
EA200702522A1 (ru) Система доставки лекарств в полость рта и способы ее применения
BR0210473A (pt) Composição compreendendo um inibidor da pde-4 e antagonista do receptor-h1 e seus usos na produção de um medicamento para o tratamento de doenças respiratórias
ATE418965T1 (de) Medikamentöse gezielte lokale lipolyse
CY1110369T1 (el) Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
BR0309595A (pt) Injeção produzida a partir de ixeris sonchifolia hance para o tratamento de doenças vasculares cardiocerebrais e doenças de fundo, e método para a produção da mesma
ATE231849T1 (de) Cyclopentabenzofuran-derivate und ihre verwendung
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
CY1112440T1 (el) Απογλυκοζυλιωμενη και αποσιαλιδωμενη μακρα πεντραξινη ρτχ3
BRPI0516545A (pt) uso de óleo de lavanda para a profilaxia e tratamento de neurastenia, distúrbios de somatização e outras doenças associadas ao estresse
HUP0402381A2 (hu) A monohidroxi-karbamazepin alkalmazása hangulati és a figyelemmel kapcsolatos rendellenességek és idegfájdalom kezelésére alkalmas gyógyszer előállítására
CY1113230T1 (el) 1-φαινυλ-2-ετεροαρυλ-υποκατεστημενα παραγωγα βενζιμιδαζολιου, η χρηση αυτων για την παρασκευη φαρμακων που χρησιμοποιουνται στη θεραπεια ανοσολογικων ασθενειων
GB0423386D0 (en) Medicament

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20030501

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2186576B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20220126